Interpace Diagnostics Gr (NASDAQ:IDXG) has been given a $3.00 price target by equities research analysts at Maxim Group in a report released on Friday, March 16th. The brokerage currently has a “buy” rating on the business services provider’s stock. Maxim Group’s target price would suggest a potential upside of 226.09% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Laidlaw began coverage on Interpace Diagnostics Gr in a research report on Thursday, February 22nd. They set a “buy” rating and a $4.50 target price on the stock. ValuEngine raised Interpace Diagnostics Gr from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright began coverage on Interpace Diagnostics Gr in a research report on Thursday, March 8th. They set a “buy” rating and a $3.00 target price on the stock.
IDXG stock traded up $0.01 during trading on Friday, reaching $0.92. 189,532 shares of the stock were exchanged, compared to its average volume of 560,217. Interpace Diagnostics Gr has a twelve month low of $0.72 and a twelve month high of $4.45. The company has a market cap of $25.25, a PE ratio of -1.14 and a beta of 1.74.
An institutional investor recently bought a new position in Interpace Diagnostics Gr stock. Sabby Management LLC acquired a new stake in shares of Interpace Diagnostics Gr (NASDAQ:IDXG) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,319,290 shares of the business services provider’s stock, valued at approximately $1,346,000. Sabby Management LLC owned approximately 4.91% of Interpace Diagnostics Gr at the end of the most recent quarter. 13.61% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/interpace-diagnostics-group-idxg-given-a-3-00-price-target-by-maxim-group-analysts.html.
Interpace Diagnostics Gr Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay.
Receive News & Ratings for Interpace Diagnostics Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Gr and related companies with MarketBeat.com's FREE daily email newsletter.